The Trump administration announced Tuesday that Medicare will pay drastically lower prices for 15 popular prescription drugs, including widely used medications for diabetes, obesity, and cancer — a move officials say will save taxpayers billions when the cuts take effect in 2027.
The negotiated prices, which represent the second round of drug pricing talks mandated by the 2022 Inflation Reduction Act, will slash costs by 44% compared to what Medicare would have paid at 2024 rates, according to the Centers for Medicare and Medicaid Services (CMS). The announcement brings the total number of drugs with government-negotiated prices to 25, with the latest batch confirmed to take effect January 1, 2027.
Among the highest-profile medications included in this round are Novo Nordisk’s Ozempic and Wegovy — the injectable drugs that have surged in popularity for treating diabetes and obesity. Under the negotiated rates, prices for these medications will plummet from their current levels of $1,000-$1,350 per month to around $350 through what the administration calls “TrumpRx,” with Medicare beneficiaries paying co-payments of just $50 monthly, the White House stated.
Billions in projected savings
The administration estimates the federal government will save approximately $8.5 billion compared to what it would have paid for these medications last year, representing a 36% reduction in costs. For Medicare enrollees themselves, out-of-pocket savings are projected to reach about $685 million, according to figures released Tuesday.
“President Trump directed us to stop at nothing to lower health care costs for the American people,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a statement. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.”
Some administration officials have cited even higher savings figures, with CMS suggesting the total benefit to federal coffers could reach $12 billion. The discrepancy appears to stem from different baseline comparisons and calculation methods.
What’s driving these substantial price reductions? Sources familiar with the negotiations suggest the administration’s willingness to walk away from talks if pharmaceutical companies wouldn’t meet certain thresholds gave federal negotiators unusual leverage. The result is particularly dramatic for the diabetes and weight-loss medications, where discounts reportedly reached 71% off previous prices.
Specific price points
The exact negotiated prices show significant reductions across the board. Ozempic and Rybelsus, both diabetes treatments, will cost Medicare $276.78 per month, while the highest dose of Wegovy — primarily prescribed for obesity — will be priced at $385.63 monthly, a dramatic drop from current rates that can exceed $1,300 per month.
Perhaps most significantly for patients with obesity and related conditions, the new prices will enable Medicare to cover Wegovy and similar medications like Eli Lilly’s Zepbound for the first time. Until now, Medicare has been prohibited from covering most weight-loss drugs, leaving millions of seniors without coverage for these increasingly popular treatments despite their proven health benefits.
“The final negotiated prices altogether represent savings of 44% on net spending that Medicare would otherwise have incurred if these prices had been in effect in 2024,” CMS explained in their announcement.
Industry reaction and implementation timeline
Pharmaceutical companies have had mixed reactions to the negotiations. While publicly expressing concerns about potential impacts on research and development, many have privately acknowledged that the Medicare market is too substantial to abandon, even at lower profit margins.
Will patients see immediate benefits? Not quite. The negotiated prices don’t take effect until January 2027, a timeline set by the original legislation. In the meantime, drug manufacturers are required to pay rebates to Medicare if they raise prices faster than inflation.
The negotiation program, which began last year with 10 drugs, is one of the signature healthcare provisions of the Inflation Reduction Act passed in 2022. The law empowers Medicare to negotiate prices for a growing number of high-expenditure drugs each year, marking a significant shift in how the government approaches pharmaceutical pricing.
“As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors,” Kennedy told reporters Tuesday evening.
For the millions of seniors who rely on these medications, 2027 can’t come soon enough. But for now, they’ll have to be satisfied with knowing that relief — however delayed — is finally on the horizon.
